Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers

Somatic mutations that activate phosphoinositide 3-kinase (PI3K) have been identified in the p110-α catalytic subunit (PIK3CA) 1. They are most frequently observed in two hotspots: the helical domain (E545K and E542K) and the kinase domain (H1047R). Although the PIK3CA mutants are transforming in vi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Engelman, Jeffrey A., Chen, Liang, Tan, Xiaohong, Crosby, Katherine, Guimaraes, Alexander R., Upadhyay, Rabi, Maira, Michel, McNamara, Kate, Perera, Samanthi A., Song, Youngchul, Chirieac, Lucian R., Kaur, Ramneet, Lightbown, Angela, Simendinger, Jessica, Li, Timothy, Padera, Robert F., García-Echeverría, Carlos, Weissleder, Ralph, Mahmood, Umar, Cantley, Lewis C., Wong, Kwok-Kin
Format:	Artigo
Language:	Inglês
Published:	2008
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2683415/ https://ncbi.nlm.nih.gov/pubmed/19029981 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.1890
Tags:	Add Tag No Tags, Be the first to tag this record!

Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers

Similar Items